Elicio Therapeutics, Inc.
ELTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ELTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies targeting mutated tumor protein p53 (p53) expressing cancers, with its lead candidate ELI-002 advancing through clinical trials.
Key risk: Cash runway limited
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Elicio Therapeutics, Inc..
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies targeting mutated tumor protein p53 (p53) expressing cancers, with its lead candidate ELI-002 advancing through clinical trials.
- Elicio Therapeutics focuses on immunotherapies for cancers expressing mutated p53, aiming to reduce recurrence risk [sec_mda · as of 2026-05-11].
- The company has incurred significant operating losses, with a net loss of $11.8 million for the three months ended March 31, 2026 [sec_mda · as of 2026-05-11].
- As of June 30, 2026, the company reported cash and equivalents of $24.0 million, shareholders' equity of $1.8 million, and total debt of $9.5 million [sec].
- Management expects cash on hand to fund operations into the fourth quarter of 2026, but additional capital will be needed thereafter [sec_mda · as of 2026-05-11].
- The company has no approved products and does not anticipate product sales until regulatory approval is obtained [sec_mda · as of 2026-05-11].
What works
- The company's immunotherapy candidates target specific oncogenic driver mutations, potentially reducing tumor recurrence risk if approved [sec_mda · as of 2026-05-11].
- Elicio has raised substantial capital historically, with aggregate net proceeds of $227.5 million from various financing sources [sec_mda · as of 2026-05-11].
What to weigh
- Elicio has a history of significant operating losses and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-05-11].
- The company's cash runway is limited, with management estimating funding only into Q4 2026, requiring additional capital that may not be available [sec_mda · as of 2026-05-11].
- No products have been approved for sale, and the company does not expect product revenue until successful development and regulatory approval [sec_mda · as of 2026-05-11].
From the filings
Quoted directly from source documents.
The company's lead candidate is ELI-002, advancing to late-stage trials.
“advance our lead product candidate, ELI-002, to late stage clinical trials;”
SEC MD&A · May 13, 2025
The company has incurred significant operating losses.
“Since inception, we have had significant operating losses. Our net loss was $11.8 million and $11.2 million for the three months ended March 31, 20”
SEC MD&A · May 11, 2026
Cash on hand is expected to fund operations into Q4 2026.
“As of the filing date of this Quarterly Report on Form 10-Q, we believe that our cash on hand will enable us to fund our operations into the fourth quarter of 2026 based on our current plan.”
SEC MD&A · May 11, 2026
The company targets mutated p53 expressing cancers.
“preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers.”
SEC MD&A · May 11, 2026
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash on hand expected to fund operations only into Q4 2026; additional capital needed thereafter [sec_mda · as of 2026-05-11].
- No approved products — No products approved for sale; no product revenue expected until regulatory approval obtained [sec_mda · as of 2026-05-11].
- History of operating losses — Significant net losses incurred since inception; losses expected to continue [sec_mda · as of 2026-05-11].
What to watch
- Progress of lead candidate ELI-002 in late-stage clinical trials [sec_mda · as of 2025-05-13].
- Ability to secure additional financing beyond Q4 2026 cash runway [sec_mda · as of 2026-05-11].
- Regulatory developments for immunotherapy candidates targeting mutated p53 [sec_mda · as of 2026-05-11].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Elicio Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Elicio Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
9.0 months
D/E 2.95 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
48
Total value held
$32.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,037,276 | $11.1M |
| susquehanna international group, llp | 373,804 | $4.0M |
| balyasny asset management l.p. | 244,814 | $2.6M |
| geode capital management, llc | 135,164 | $1.4M |
| renaissance technologies llc | 121,631 | $1.3M |
| jane street group, llc | 115,600 | $1.2M |
| millennium management llc | 92,762 | $992K |
| citadel advisors llc | 78,078 | $835K |
| marshall wace, llp | 74,512 | $797K |
| vanguard fiduciary trust co | 69,189 | $740K |
Showing top 10 of 48 institutional holders of Elicio Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 12.9%
- Days to cover
- 13.2
- Shares short
- 1,658,153
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Elicio Therapeutics, Inc.?
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapies targeting mutated tumor protein p53 (p53) expressing cancers, with its lead candidate ELI-002 advancing through clinical trials.
What is Elicio Therapeutics, Inc.'s lead drug candidate?
Elicio Therapeutics, Inc.'s most advanced tracked candidate is eli-002 (Phase 2) for Minimal Residual Disease.
Who is the CEO of Elicio Therapeutics, Inc.?
Mr. Robert T. Connelly is the chief executive officer of Elicio Therapeutics, Inc. (ELTX).
Where is Elicio Therapeutics, Inc. headquartered?
Elicio Therapeutics, Inc. (ELTX) is headquartered in Boston, MA, United States.
What therapeutic areas does Elicio Therapeutics, Inc. focus on?
Elicio Therapeutics, Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.